Aarkstore.com announces, The Latest market research report is available inits vast collection:Pancreatic Cancer – Pipeline Review, H1 2012You can also request for sample page of above mention reports firstname.lastname@example.orgSummaryGlobal Markets Direct’s, Pancreatic Cancer - Pipeline Review, H1 2012, provides anoverview of the Pancreatic Cancer therapeutic pipeline. This report providesinformation on the therapeutic development for Pancreatic Cancer, complete withlatest updates, and special features on late-stage and discontinued projects. It alsoreviews key players involved in the therapeutic development for Pancreatic Cancer.Pancreatic Cancer - Pipeline Review, H1 2012 is built using data and informationsourced from Global Markets Direct’s proprietary databases, Company/Universitywebsites, SEC filings, investor presentations and featured press releases fromcompany/university sites and industry-specific third party sources, put together byGlobal Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Pancreatic Cancer.- A review of the Pancreatic Cancer products under development by companies anduniversities/research institutes based on information derived from company andindustry-specific sources.- Coverage of products based on various stages of development ranging fromdiscovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combinedtherapeutics.Table of contents:List of Tables 5List of Figures 5Introduction 6Global Markets Direct Report Coverage 6Metastatic Hormone Refractory Prostate Cancer Overview 7Therapeutics Development 8An Overview of Pipeline Products for Metastatic Hormone Refractory ProstateCancer 8Metastatic Hormone Refractory Prostate Cancer Therapeutics under Developmentby Companies 10Metastatic Hormone Refractory Prostate Cancer Therapeutics under Investigationby Universities/Institutes 11Late Stage Products 13Comparative Analysis 13Mid Clinical Stage Products 14Comparative Analysis 14Early Clinical Stage Products 15Comparative Analysis 15Metastatic Hormone Refractory Prostate Cancer Therapeutics – Products underDevelopment by Companies 16Metastatic Hormone Refractory Prostate Cancer Therapeutics – Products underInvestigation by Universities/Institutes 17Companies Involved in Metastatic Hormone Refractory Prostate CancerTherapeutics Development 18Genentech, Inc. 18Oxford BioMedica plc 19Millennium Pharmaceuticals, Inc. 20Metastatic Hormone Refractory Prostate Cancer – Therapeutics Assessment 21Assessment by Monotherapy Products 21Assessment by Combination Products 22Assessment by Route of Administration 23
Assessment by Molecule Type 25Drug Profiles 27TAK-700 - Drug Profile 27Product Description 27Mechanism of Action 27R&D Progress 27AZD2171 + Docetaxel + Prednisone - Drug Profile 29Product Description 29Mechanism of Action 29List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Pipeline Review, H1 2012http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H12012&PubId=&pagenum=1Erosive Oral Lichen Planus – Pipeline Review, H1 2012Pancreatic Cancer – Pipeline Review, H1 2012Metastatic Hormone Refractory Prostate Cancer – Pipeline Review, H1 2012Myasthenia Gravis – Pipeline Review, H1 2012Dental Plaque – Pipeline Review, H1 2012
Esophagitis – Pipeline Review, H1 2012Retinitis Pigmentosa (Retinitis) – Pipeline Review, H1 2012Cellulite – Pipeline Review, H1 2012HIV Pain – Pipeline Review, H1 2012Tropical Spastic Paraparesis – Pipeline Review, H1 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcarehttp://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals andHealthcare&PubId=&pagenum=1For More details Plz do contact :Aarkstore EnterpriseLavanyaPhone:08149852585Email: email@example.com